- FLML has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.8 million.
- FLML has traded 83,259 shares today.
- FLML is trading at 5.01 times the normal volume for the stock at this time of day.
- FLML is trading at a new high 7.54% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in FLML with the Ticky from Trade-Ideas. See the FREE profile for FLML NOW at Trade-Ideas More details on FLML: Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology primarily in the United States and Europe. FLML has a PE ratio of 9. Currently there are 4 analysts that rate Flamel Technologies a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Flamel Technologies has been 305,400 shares per day over the past 30 days. Flamel has a market cap of $349.3 million and is part of the health care sector and drugs industry. Shares are down 22.7% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Flamel Technologies as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Highlights from the ratings report include:
- FLML's very impressive revenue growth greatly exceeded the industry average of 2.7%. Since the same quarter one year prior, revenues leaped by 1362.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, FLAMEL TECHNOLOGIES SA -ADR's return on equity significantly exceeds that of both the industry average and the S&P 500.
- FLAMEL TECHNOLOGIES SA -ADR reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. However, we anticipate underperformance relative to this pattern in the coming year. During the past fiscal year, FLAMEL TECHNOLOGIES SA -ADR turned its bottom line around by earning $0.86 versus -$2.55 in the prior year. For the next year, the market is expecting a contraction of 89.5% in earnings ($0.09 versus $0.86).
- FLML's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 47.08%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- Currently the debt-to-equity ratio of 1.82 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.11, which shows the ability to cover short-term cash needs.
- You can view the full Flamel Technologies Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.